CB Insights Genomics Tech 2017

GENOMICS: THE NEXT PHASE OF
PERSONALIZED MEDICINE
Emerging trends, players, and business models
WEBINAR RECORDING WILL BE DISTRIBUTED
IMMEDIATELY AFTER
The presentation will also be sent to you. Feel free to share with colleagues. The resolution of
some slides may be suboptimal due to the webinar software. Those slides will look fine in the
presentation that we send you.
http://support.citrixonline.com/en_US/Webinar
#cbigenomics www.cbinsights.com 2
JOIN THE CONVERSATION ON TWITTER
@cbinsights
@nikillinit
#genomics
The technology market
intelligence platform.
CB Insights software lets you predict, discuss, and
communicate emerging technology trends using data
in ways that are beyond human cognition.
www.cbinsights.com 4
A FEW OF OUR HAPPY CUSTOMERS
The most publicly referenceable customers of anyone in the industry
With CB Insights we can quickly and reliably

aggregate data across the investing landscape, from
sector trends to financing activity. The intuitive user
interface and robust set of features have made it a
go-to resource for our team, and the customer
support is second to none...
Kate Barrett
Director, New Enterprise Associates
#cbigenomics See what other customers have to say at http://www.cbinsights.com/customer-love www.cbinsights.com 5

ABOUT THE PRESENTER
Nikhil Krishnan
Research Analyst, CB Insights
Focuses on Healthcare, Consumer Packaged Goods, and VC Trends
Published research and data analysis have been featured in The
New York Times, Wall Street Journal, Financial Times, Bloomberg,
and CNBC, among other major media outlets
@nikillinit
Graduate of Columbia University
nkrishnan@cbinsights.com
TABLE OF CONTENTS
9 Macro Trends Enabling The Genomics Revolution
18 Investment Trends, Exits, And Active Investors In
Private Markets
29 The Role Of Corporates
40 Business Models And Approaches + 23andMe analysis
57 The Role Of Government
64 Genomics Looking Ahead
WHAT IS GENOMICS (AS WE DEFINE IT)?
Well be focusing on genomics as it relates to the creation

and analysis of genetic data
More specific focus

Gene-based diagnostic tests
Genetic sequencing
Data analysis tools for genetic data
We will not be focusing on the application layer

(bioengineering, gene therapies, etc.)
Macro Trends
The key factors that are enabling the wave of genomics developments today
GENETICS CAN HELP
US BETTER
UNDERSTAND OUR
HEALTH
Our DNA is believed to be

one of the most
important parts in
understanding our
health. It can potentially
help us in everything
from family planning, to
disease risk, to
understanding our
response to medications,
and more.
#cbigenomics Source: https://www.genome.gov/images/content/genetic_testing.jpg www.cbinsights.com 10

THE COST OF
SEQUENCING HAS
DROPPED
DRAMATICALLY
Thanks to technological
advances, the cost of
sequencing has dropped
dramatically since the
days of the Human
Genome Project. It now
costs closer to $1000
compared to $10M+ a
decade ago.
#cbigenomics source: https://www.genome.gov/sequencingcostsdata/ www.cbinsights.com 11

MORE GENOMIC DATA
IS NOW AVAILABLE
More human genomes

continue to be
sequenced as the price
of sequencing drops.
Predictions suggest
exponential growth in the
number of human
genomes sequenced in
future years.
#cbigenomics source: http://ark-invest.com/genomic-revolution/declining-costs-of-genome-sequencing www.cbinsights.com 12

GENOMICS AND GENETICS CHATTER GENE CHATTER IS
REACHING HIGHS
Interest in genomics has

increased significantly,
due to developments in
gene editing, more
studies conducted with
larger datasets, and
clinical applications of
gene therapies. While
genetics and genomics
are in the spotlight, a
nascent but increasing
interest is different
applications in the area
of genetics.
TESTING HAS STILL
ONLY HIT A SMALL
PART OF THE MARKET
Out of 1000+ surveyed,

only 15% had taken a
genetic test, almost all
went through their
physician. This
population was also
relatively high-income
and insured.
#cbigenomics Source: Rock Health www.cbinsights.com 14

PHYSICIAN AND
CONSUMER
MOTIVATIONS
Physician use of genetics

is driven by preventive
medicine and disease
treatment; consumer use
is driven by curiosity or
ancestry.
#cbigenomics Source: Rock Health www.cbinsights.com 15

CONSUMERS ARE
LOOKING AT
MANAGEABLE DISEASE
MARKERS
Identifying chronic
diseases is a main area
of interest in genomics,
particularly for diseases
that drive up health
expenditure drastically
and that may be
manageable through
lifestyle changes.
#cbigenomics Source: UBS Genomics 2.0 Consumer Genomics www.cbinsights.com 16

GENOMICS IS JUST BEGINNING
We are making discoveries every day that

surprise us because nobody has had these
data sets before Nobody has been able to
ask these questions before. With our first
20,000 genomes we have just completed the
first lap in what will be a very long race."
J. Craig Venter
CEO, Human Longevity
#cbigenomics Source: Wired www.cbinsights.com 17

Investment Overview
Funding trends, active players, and notable exits
Global equity funding since 2013:
$6.5 BILLION
across
473 DEALS
GENOMICS ANNUAL GLOBAL FINANCING HISTORY GENOMICS DEALS HIT
2013 - 2017 YTD (7/19/17) HIGH IN 2015, 2016
121
SEES MEGAROUNDS
114
(Full-Year Run Rate)
112 Funding into genomics in
$3251 2017 has already
94 (Full-Year Run Rate)
surpassed the
81 cumulative funding of the
previous year due to
65 mega deals in cancer
detection companies like
GRAIL and Freenome.
Deals have remained
stagnant, with 2017 on
track to hit 115 by the
year end.
$568 $1,168 $1,237 $1,703 $1,852
2013 2014 2015 2016 2017 YTD

Disclosed Funding ($M) Deals
#cbigenomics source: CB Insights www.cbinsights.com 20

GENOMICS DEAL SHARE BY STATE MASSACHUSETTS
2013 - 2017 YTD (7/19/2017)
POSITIONS ITSELF FOR
GENOMICS
While most of the

genomics deals are
California 28% happening in California,
Massachusetts Massachusetts has
New York
43% claimed its spot as a
Utah clear second, likely due
Missouri to its university research
North Carolina 3% initiatives and large
Other 4% biotech presences
amongst others. Nearly
4%
40% of genomics deals
5%
12% happen outside of the 3
major markets (NY, CA,
MA).

GENOMICS: TOP DEALS
2013-2017 YTD (as of 7/19/2017) GENOMICS DEALS ARE
COMPANY AMOUNT/ROUND QUARTER SELECT INVESTORS GETTING BIGGER
McKesson Ventures,
$914M/Series B Q1'17
Amazon, Merck & Co.
The largest genomics
deals are starting to get
bigger, with GRAIL
Softbank Group,
$360M/Series E Q2'17 Orbimed Advisors, leading with more than
Sequoia Capital $1B in total financing.
Recent large deals in the
Sequoia Capital space have been focused
$320M/Unattributed Q2'14 China, Shenzhen
Capital
on specific applications
for genomics (fertility,
cancer detection, etc.) as
Celgene, Draper
$220M/Series B Q2'16 Fisher Jurvetson, opposed to only
Illumina sequencing or building a
genetic database.
Lee Equity Partners,
$200M/Series B Q4'16 Reproductive Biology
Associates

GENOMICS ANNUAL EXIT HISTORY GENOMICS EXITS MAY
2013 - 2017 YTD (7/19/2017)
SLOW DOWN
After consecutive years

of genomic exits
increasing, 2017 is
starting to slow down.
There have only been 15
28
exits in 2017 so far,
(Full-Year Projection) putting it on track to fall
below the 32 exit mark
set in 2016. 2017 has
seen some acquisitions
by other private
companies, including the
acquisitions of Spiral
15 22 29 32 15
Genetics, Ommdom, and
2013 2014 2015 2016 2017
Genos.
Genomics Annual Exit History

NOTABLE EXITS
$1.8B Valuation
$1B Valuation
IPO
$872M
$415M Acquisition Valuation
REVERSE
$410M Acquisition
MERGER
$619M
Valuation
GENOMICS GLOBAL DEAL COUNT GENOMICS DEALS
2013 - 2017 YTD (7/19/17) SHIFT FROM EARLY TO
LATE STAGE
63
60 Interest in genomics in
the last couple of years
50 led to many new early
stage financings,
jumping in 2015 and
35 2016. This trend has
32
27 slowed however, and
25
23 23 instead 2017 has seen
22
18 17 more deals happening in
15
11 12 the mid and late stage
8 8 8 areas as companies
10 6
mature.
2013 2014 2015 2016 2017 YTD
Early Stage Mid Stage Late Stage Other

UNIQUE INVESTORS INTO GENOMICS NUMBER OF
2013 - 2017 YTD (7/19/17) INTERESTED
225
INVESTORS SLOWS
197 While more and more
175 unique investors looked
for a genomics company
150
to add to their portfolio,
this pace has slowed
down between 2015 and
2016 with the last year
dropping below 200
unique investors.
2013 2014 2015 2016

Unique Investors Into Genomics

UNIQUE INVESTORS INTO GENOMICS VCS SLOW DOWN, NEW
2013 - 2017 YTD (7/19/17) INVESTORS JUMP IN
101
90 92 While venture investors

have been the main
79 84
82 source of capital for
most genomics startups,
59 2016 saw a slowdown in
57
the number of interested
firms. Instead, other
investors, such as family
32 31 offices, asset
26
management, hedge
14 funds, etc. overtook
them. Corporate activity
has remained steady.
2013 2014 2015 2016
VC Corporation/Corporate VC Other

MOST ACTIVE GENOMICS INVESTORS THERE IS A WIDE
Firms ranked by unique investments, 2013 2017 YTD (7/20/2017)
RANGE OF INVESTOR
TYPES
Because genomics is
both a cutting edge
technology/software
issue as well as a
biological one, the field
sees a wide array of
investors from both sides
and all types. Genomics
companies business
models are also both
enterprise and direct-to-
consumer, attracting
investors that specialize
in either.

The Role Of Corporates
Pharma, insurance, and tech giants are just some of the strategic investors getting involved
CORPORATE PARTICIPATION IN GENOMICS DEALS CORPORATES SLOW
2013 - 2017 YTD (7/19/17)
THEIR INVESTMENT
ACTIVITY
17% 20%
22% 23% 24% Corporates increased
their participation in
genomics deals through
2016, taking part in
nearly 25% of all
genomics deals. This
year however, corporates
83% 80%
78% 77% 76% have slowed down.
Of the top 10 largest

deals, corporates were
involved in 6 of them,
including InVitae, Human
2013 2014 2015 2016 2017 YTD Longevity, and Oxford
No Corporate Participation Corporate Participation Nanopore.
#cbigenomics Source: CB Insights www.cbinsights.com 30

3
Vitagene Encoded
Genomics
Trace Genomics Biome Makers Urology
Diagnostics
THERE IS A DIVERSE
Illumina Accelerator
RANGE OF MOST
MOST ACTIVE GENOMICS CORPORATES 4 ACTIVE CORPORATE
Firms ranked by unique investments, 2013 MOST
MOST ACTIVE GENOMICS CORPORATES 2017 ACTIVE GENOMICS CORPORATES
YTD (7/20/2017) Fabric Genomics Epic Sciences Stratos Horizon
Firms ranked by unique investments, 2013 - 2017 YTD (7/20/2017)

INVESTORS
Genomics Discovery
Firms ranked by unique investments, 2013 - 2017 YTD (7/20/2017)
Roche Venture Fund
Rank Investor Companies Rank Investor Companies
1 51
Veritas
GRAIL Genetics Baebies
ReadCoor Singlera
Kallyope Human Desktop Oxford Nanopore 23andMe
The most active
corporates in the
GRAIL Baebies Kallyope Human Desktop Oxford Nanopore 23andMe
Longevity Genetics Technologies Genomics Longevity Genetics Technologies
Illumina Illumina
Lilly Asia Ventures
2 52
genomics space run the
Freenome 23andMe GRAIL Genomics
Medicine Ireland
Cambridge
Epigenetix
DNAnexus Freenome
GRAIL
23andMe
Inivata
GRAIL
Atlas Genetics
Genomics
Medicine Ireland
Cambridge
Epigenetix
DNAnexus
gamut from lab services

to pharma, and there are
Google Ventures Google Ventures
Johnson & Johnson Innovation
3
Vitagene Encoded Trace Genomics Biome Makers Urology
53
Vitagene
Human
Encoded Trace Genomics Biome Makers
Veracyte RainDance
Urology
also several tech
companies (Google, GE)
Genomics Diagnostics Genomics Diagnostics
Longevity Technologies
Illumina Accelerator Illumina Accelerator

GE Ventures
4 4 that are active in the

Roche Venture Fund
Fabric Genomics Epic Sciences Stratos
Genomics
Horizon
Discovery
Roche Venture Fund

Fabric Genomics Epic Sciences Stratos
Genomics
Horizon
Discovery
space. Many large
genomics companies like
5 5
Veritas Genetics ReadCoor Singlera
Genomics
Veritas Genetics ReadCoor Singlera
Genomics
GRAIL and Human
Lilly Asia Ventures Lilly Asia Ventures
Longevity see overlap
5
GRAIL Inivata Atlas Genetics
5
GRAIL Inivata Atlas Genetics
from several corporate
Johnson & Johnson Innovation Johnson & Johnson Innovation investors in the table.
5 5
#cbigenomics
Human
Longevity
Veracyte RainDance
Technologies
Source: CB Insights Human Veracyte RainDance
Longevity Technologies
GENOMICS IS ONE
AREA OF DIGITAL
HEALTH THAT PHARMA
IS INTERESTED IN
Pharma companies have

typically strayed away
from digital health as a
whole, but genomics is
one area that many
pharma corporates have
invested in or stated their
interest in. Some
companies, like Roche,
are particularly active in
this area.
#cbigenomics Source: www.cbinsights.com/blog/big-pharma-investing-private-markets/ www.cbinsights.com 32

INSURERS ARE SEEKING PARTNERSHIPS
Multi-year agreement to offer

whole genome sequencing to Color Genomics has started
MassMutual customers, accepting insurance for its
employees, and financial Hereditary Cancer Test.
professionals at reduced rate.
Already partnered with multiple
MassMutual will not receive any insurers, currently seeking
genomic data at the moment. Medicare & Medicaid coverage.
#cbigenomics 33
OTHER NOTABLE CORPORATE PARTNERSHIPS
ILLUMINA INCREASES
THEIR PRIVATE
Jan 2010 July 2012 Jan 2015 July 2017 MARKET ACTIVITY
Illumina has ramped up

its activity in private
markets, acquiring
companies through its
parent company and
setting up investment
arms.
The company has been

involved in 50 private
market transactions and
invested in most of the
large genomics
companies.

ILLUMINA MOVES UP
AND DOWN THE STACK
Illumina spin-off GRAIL

is moving closer to the
sample collection part of
the equation, and Helix
plans to be the app store
for genetic data, allowing
APIs to provide analysis.
Both are well capitalized
and are moving quickly.
#cbigenomics Source: Company websites www.cbinsights.com 36

GRAIL HAS RAISED
FROM INVESTORS
ACROSS THE BOARD
GRAIL has raised more

than $1B from investors
across the healthcare
spectrum, well known
venture firms, and even
tech companies like
Amazon. The company is
also expanding its Asian
presence through
Tencent and recently
merged with Cirina, a
Chinese blood
diagnostics company.

GRAIL IS STARTING
CLINICAL TRIALS
In addition to raising
significant amounts of
money, GRAIL is also
recruiting for several
large scale clinical trials
in partnership with
notable collaborators like
the Mayo Clinic and
Cleveland clinic to test its
technology. The
company suggests it will
have a product by 2019,
depending on trials.

HELIX LAUNCHES ITS
MARKETPLACE
Helix has rolled out its

product, offering a
marketplace of several
different services from a
variety of companies to
interpret genetic data.
The use cases range
from ancestry and
curiosity to more clinical
applications like family
planning and
understanding disease
predispositions.

Business Models and Approaches
Pharma, insurance, and tech giants are just some of the strategic investors getting involved
COMPANIES ARE
INVOLVED IN AT LEAST
SAMPLE SEQUENCE SOFTWARE ONE PART OF THE
CHAIN
Companies generally
focus on one specific
part of the data capture
chain, but can also
verticalize into one
specific area and
integrate the entire
process.
MOST GENOMICS
COMPANIES CHOOSE
BETWEEN WELLNESS
AND MEDICAL
RELEVANCE
Most genomics
companies base their
business model and
CURIOSITY/WELLNESS MEDICAL RELEVANCE
market approach through
the lens of wellness
(customer curiosity,
actionable lifestyle
recommendations)
and/or medical relevance
(disease risk, lab
analysis, etc.) each with
pros and cons.
WELLNESS HAS LESS
REGULATION, BUT
TOUGHER BUSINESS
Genetics companies
targeting wellness can
typically go straight to
consumers with less FDA
CURIOSITY/WELLNESS stringency (for now) and
do not provide
diagnoses. The
consumer typically pays
for these tests
themselves, which also
means they have to be at
a cheaper price point and
have less actionability
with the data.
MEDICAL RELEVANCE
HAS LONGER
REGULATORY AND
SALES CYCLES
Companies that provide

analysis, diagnosis, and
interpretation of results
MEDICAL RELEVANCE typically have bigger and
better-funded customers
(labs, providers, etc.) but
also have a higher
regulatory burden and
must sell within the
health system.
THE MIDDLE IS A
NASCENT AREA
Combining medical-
grade interpretations and
a patient-driven approach
GENOTYPE yields preventive
GUIDED medicine thats
MEDICINE & potentially reimbursable
WELLNESS by insurance.
ANALYTICS SOFTWARE SOFTWARE FOCUSED
ON GENOMICS
Analytics software
provides tools that help
providers and
researchers make sense
of their data by
aggregating multiple
data streams.

DNA-BASED LIQUID LIQUID BIOPSIES USING
CANCER BIOPSIES CTDNA
Some companies are

trying to detect cancers
earlier through non-
invasive biopsies by
finding circulating pieces
of DNA shed by cancer
cells in the bloodstream.

NEXT GENERATION NEW SEQUENCERS
SEQUENCERS
Sequencing startups are

trying to reduce the cost
of genetic sequencing
even further using new
techniques or making
sequencing machines
themselves smaller and
more portable.

GENE SCREENING GENETIC SCREENING
AND WELLNESS
Gene screening
companies are analyzing
samples from patients to
determine their carrier
status and other
potential predispositions
to help people better plan
for their health.

NON-HUMAN GENOMICS GENOMICS IN PLANTS,
ANIMALS, FUNGI, ETC.
A few companies in the

genomics space are
going for the less
regulated route by
applying genomics to
other non-human
biological systems.
Experiments here can be
done with faster
feedback loops and at
larger scale with lower
risk. Commercialization
and go-to-market
strategies are also more
clear, with defined
buyers.
23andMe
23andMes journey highlights the tough aspects of
building a direct-to-consumer genetic testing market.
FDA COMPLIANCE
PROVES TO BE A BIG
HURDLE
FDA APPROVAL FOR
FDA CRACKDOWN
10 MORE DISEASES
Providing analysis
directly to consumers
about disease
23ANDME RAISES predispositions based on
FDA APPROVAL
TO TEST BLOOM SYNDROME genetic data requires the
regulatory oversight of
the FDA. 23andMe was a
pioneer here, first getting
approval for their Bloom
Syndrome test and more
recently receiving
approval for 10 more
tests, including
Parkinsons, Gaucher
disease type 1, and more.

COMPLIANCE RISK IS
REFLECTED IN
FINANCING TERMS
Post-FDA approval,
23andMe saw a massive
VALUATION valuation jump, and the
JUMP OF 194% scope of the company
POST FDA
also broadened.
23andMe also received a
grant from the NIH to
open their de-identified
data to partners and a
recent grant from the
National Human Genome
Research Institute. The
company is poised to
raise another round
soon.

23ANDME IS NOW
BUILDING THEIR
GENETIC DATABASE
Since the FDA

intervention the number
of customers has more
than doubled and
23andMe has built out a
formidable database and
developed direct
relationships with more
and more consumers.
#cbigenomics source: https://www.technologyreview.com/s/601506/23andme-sells-data-for-drug-search/ www.cbinsights.com 54

IN THE NEWS
CELMATIX AND 23ANDME ANNOUNCE
LAUNCH OF FERTILITY RESEARCH
COMMUNITY
February 22, 2017
23ANDME CAN GET
INTO SERVICES
With a large database

and direct relationships
with consumers,
23andMe could get into
the services category.
The company already
has a patent in fertility
matchmaking, but could
move into other services,
like genetic counseling,
family planning, and
more.
#cbigenomics source: https://www.technologyreview.com/s/601506/23andme-sells-data-for-drug-search/ www.cbinsights.com 56

Government And Genomics
Regulations and initiatives the government is taking in genomics
GENOMICS AS PART OF THE PRECISION
MEDICINE INITIATIVE
And just like analyzing our DNA teaches us more
about who we are than ever before, analyzing data
from one of the largest research populations ever
assembled will teach us more about the connections
between us than ever before. And this new
information will help doctors discover the causes,
and one day the cures, of some of the most deadly
diseases that we face.
Barack Obama
Former President Of The United States
#cbigenomics Source: Whitehouse.gov www.cbinsights.com 58

NIH BUILDING A MASSIVE GENOTYPE/PHENOTYPE DATABASE
All of Us is a precision medicine research program that will collect medical records, genetic data,
biometrics, urine samples, etc. to build a longitudinal genotype/phenotype dataset thats inclusive
of typically marginalized groups.
59
GRANTS PLAY A BIG
ROLE FOR GENOMICS
COMPANIES
Grants play an important

role for genomics
companies, with more
than 100 grants given
and some larger than
$10M. As the
government sees the
benefits of genomics, we
can expect to see more
funds earmarked for
these ventures going
forward.

REGULATORY BURDEN
PLAYS LARGE ROLE IN
GENOMICS
Multiple regulatory
bodies govern different
steps in the genetic
analysis process, from
sequencing to
interpretation to
marketing.
Genomics companies
are affected by multiple
laws, including GiNA,
CLIA, etc.
#cbigenomics Source: https://www.genome.gov/10002335/regulation-of-genetic-tests/ www.cbinsights.com 61

REGULATIONS ARE
SHIFTING QUICKLY
The FDA recently put out

a draft guidances for
next-generation
sequencing companies,
allowing the use of FDA-
recognized standard
databases and approval
pathways for companies.
Source: http://www.mlo-online.com/the-push-to-reconcile-the-gap-in-ldt-regulations,
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm509814.htm
HOW GENETIC DATA CAN BE USED IS STILL UP IN
THE AIR
Employees given Potentially no limit on
< 30% insurance employee wellness
Does not apply to discount for sharing program incentives
life insurance. medical information offered for access to
with employer genetic data.
1996 2008 2010 2015 Today

Preserving
Employee Wellness
Programs Act
(introduced to
Congress)
#cbigenomics 63
Genomics:
LOOKING AHEAD
GENE-BASED DNA-BASED
GENETIC COUNSELING GENE EDITING THE APPLICATION
THERAPIES AND DRUGS DRUGS AND THERAPIES
LAYER IS BEING BUILT
As the technology itself

improves and the
amount of data
increases, well start
seeing more applications
and services built on top
of genomes. Better
DNA DATA STORAGE BIOMETRIC-BASED GENE-BASED medicines, health
SECURITY LIFESTYLE PLANS planning, and individual
solutions will come out
of this movement.
CRISPR COMPANIES ARE MATURING GENE EDITING IS
BECOMING A REALITY
Several companies have

successfully raised
capital and hit public
markets as CRISPR has
demonstrated that gene
editing is no longer
science fiction.
Genomics companies
are seeking to
understand how genes
are expressed so that
CRISPR can be used to
make edits.
HOW MUCH SHOULD
WE RELY ON GENETIC
DATA?
Were still in the early

days of understanding
the impact of genetics in
medicine. Genetics cant
explain everything, so
understanding how other
variables such as
environment, upbringing,
etc. impact genetics will
be crucial. Genome Wide
Association Studies
(GWAS) and mapping
regulatory networks in
cells will help us better
understand.
Source: http://www.nejm.org/doi/full/10.1056/NEJMoa1310669#t=articleDiscussion,,
#cbigenomics http://www.nejm.org/doi/full/10.1056/NEJMoa1311386#t=articleDiscussion
WHO OWNS THAT DATA
AND HOW IS IT BEING
USED?
Genetics could arguably

be one of the most
personalized datasets
out there. Who owns the
data and how its used
will be a crucial question
in the next decades.
#cbigenomics Source: https://www.fastcompany.com/3055710/if-you-want-life-insurance-think-twice-before-getting-genetic-testing www.cbinsights.com 68

CBINSIGHTS.COM
@ cbinsights
@ @ nikillinit
nkrishnan@cbinsights.com
#cbigenomics

CB Insights Genomics Tech 2017

Hochgeladen von

Dokumentinformationen

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

CB Insights Genomics Tech 2017

Hochgeladen von

Copyright:

Verfügbare Formate

GENOMICS: THE NEXT PHASE OF

With CB Insights we can quickly and reliably

#cbigenomics See what other customers have to say at http://www.cbinsights.com/customer-love www.cbinsights.com 5

Well be focusing on genomics as it relates to the creation

More specific focus

We will not be focusing on the application layer

Our DNA is believed to be

#cbigenomics Source: https://www.genome.gov/images/content/genetic_testing.jpg www.cbinsights.com 10

#cbigenomics source: https://www.genome.gov/sequencingcostsdata/ www.cbinsights.com 11

More human genomes

#cbigenomics source: http://ark-invest.com/genomic-revolution/declining-costs-of-genome-sequencing www.cbinsights.com 12

Interest in genomics has

Out of 1000+ surveyed,

#cbigenomics Source: Rock Health www.cbinsights.com 14

Physician use of genetics

#cbigenomics Source: Rock Health www.cbinsights.com 15

#cbigenomics Source: UBS Genomics 2.0 Consumer Genomics www.cbinsights.com 16

We are making discoveries every day that

#cbigenomics Source: Wired www.cbinsights.com 17

2013 2014 2015 2016 2017 YTD

#cbigenomics source: CB Insights www.cbinsights.com 20

While most of the

#cbigenomics source: CB Insights www.cbinsights.com 21

#cbigenomics source: CB Insights www.cbinsights.com 22

After consecutive years

#cbigenomics source: CB Insights www.cbinsights.com 23

Early Stage Mid Stage Late Stage Other

#cbigenomics source: CB Insights www.cbinsights.com 25

2013 2014 2015 2016

#cbigenomics source: CB Insights www.cbinsights.com 26

90 92 While venture investors

#cbigenomics source: CB Insights www.cbinsights.com 27

#cbigenomics source: CB Insights www.cbinsights.com 28

Of the top 10 largest

#cbigenomics Source: CB Insights www.cbinsights.com 30

Firms ranked by unique investments, 2013 - 2017 YTD (7/20/2017)

gamut from lab services

Illumina Accelerator Illumina Accelerator

4 4 that are active in the

Roche Venture Fund

Pharma companies have

#cbigenomics Source: www.cbinsights.com/blog/big-pharma-investing-private-markets/ www.cbinsights.com 32

Multi-year agreement to offer

Illumina has ramped up

The company has been

#cbigenomics Source: CB Insights www.cbinsights.com 35

Illumina spin-off GRAIL

#cbigenomics Source: Company websites www.cbinsights.com 36

GRAIL has raised more

#cbigenomics Source: Company websites www.cbinsights.com 37

#cbigenomics Source: Company websites www.cbinsights.com 38

Helix has rolled out its

#cbigenomics Source: Company websites www.cbinsights.com 39

Companies that provide

#cbigenomics Source: CB Insights www.cbinsights.com 46

Some companies are

#cbigenomics Source: CB Insights www.cbinsights.com 47

Sequencing startups are

#cbigenomics Source: CB Insights www.cbinsights.com 48

#cbigenomics Source: CB Insights www.cbinsights.com 49

A few companies in the

#cbigenomics source: CB Insights www.cbinsights.com 52

#cbigenomics source: CB Insights www.cbinsights.com 53

Since the FDA